Abstract
Background—Does the use of the histamine H2 receptor antagonist ranitidine improve the outcome of patients with gastric cancer? Patients—A total of 222 patients with gastric cancer who had received radical or palliative resection or who were deemed inoperable at presentation. Setting—Hospitals within Yorkshire, the participating clinicians being members of the Yorkshire GI Tumour Group. Methods—A multicentre prospective randomised double blind trial comparing ranitidine 150 mg twice daily with placebo twice daily was undertaken. The principal outcome measures were survival and survival excluding those who died within 30 days of operation. Results—The median survival (95% confidence intervals) was 331 (232 to 393) days for patients in the ranitidine group compared with 187 (143 to 269) for those in the placebo group. The difference in survival was not statistically significant (p = 0.225). When patients who died within 30 days of operation were excluded (21in the placebo group, 15 in the ranitidine group), the difference in survival remained not significant (p = 0.358). No subgroup could be identified who significantly benefited from treatment, but for patients with stage VIa cancer the median survival was 134 days with placebo compared with 313 days with ranitidine (p= 0.073). Conclusion—This study does not show significant benefit from the use of ranitidine for gastric cancer but further larger studies may be indicated.
Keywords: rantitidine; cimetidine; H2 histamine receptor antagonist; gastric cancer
Full Text
The Full Text of this article is available as a PDF (78.8 KB).
Figure 1 .
Overall survival by life table analysis of the patients in the study.
Figure 2 .
Overall survival by life table analysis of the patients in the study who survived 30 days after operation.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Colin-Jones D. G., Langman M. J., Lawson D. H., Logan R. F., Paterson K. R., Vessey M. P. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut. 1992 Sep;33(9):1280–1284. doi: 10.1136/gut.33.9.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gifford R. R., Tilberg A. F. Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production. Surgery. 1987 Aug;102(2):242–247. [PubMed] [Google Scholar]
- Griswold D. E., Alessi S., Badger A. M., Poste G., Hanna N. Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol. 1984 Jun;132(6):3054–3057. [PubMed] [Google Scholar]
- Hahm K. B., Lee S. I., Chung J. P., Kim W. H., Kim J. H., Park I. S. Comparison of immunomodulative effects of histamine-2 receptor antagonists in gastric cancer patients: focus on the lymphoblastogenesis and cytotoxicity of peripheral blood mononuclear cells. Int J Immunopharmacol. 1994 Dec;16(12):985–993. doi: 10.1016/0192-0561(94)90077-9. [DOI] [PubMed] [Google Scholar]
- Svendsen L. B., Ross C., Knigge U., Frederiksen H. J., Graversen P., Kjaergård J., Luke M., Stimpel H., Sparsø B. H. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum. 1995 May;38(5):514–518. doi: 10.1007/BF02148852. [DOI] [PubMed] [Google Scholar]
- Tønnesen H., Knigge U., Bülow S., Damm P., Fischerman K., Hesselfeldt P., Hjortrup A., Pedersen I. K., Pedersen V. M., Siemssen O. J. Effect of cimetidine on survival after gastric cancer. Lancet. 1988 Oct 29;2(8618):990–992. doi: 10.1016/s0140-6736(88)90743-x. [DOI] [PubMed] [Google Scholar]
- Watson S. A., Wilkinson L. J., Robertson J. F., Hardcastle J. D. Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut. 1993 Aug;34(8):1091–1096. doi: 10.1136/gut.34.8.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]